Biotechnology US biotech Arrowhead Pharmaceuticals yesterday revealed receiving a written notice from US healthcare giant Johnson & Johnson’s Janssen unit that it has terminated its rights to JNJ-75220795, now called ARO-PNPLA3, under the October 2018 research collaboration and option agreement, as part of J&J’s strategic R&D portfolio review. 16 February 2023